*Results from a multi-center, open-label, phase IV study of patients with AKs on the face or scalp. The study opjectives were to characterize further the efficacy and safety of ALA-PDT by extending previous work. Sixty percent of the patients received a second ALA-PDT treatment, limited to the target AKs still present at month 2.
Below are white papers, clinical studies and other published reports on the success of Levulan and Blu-U.
Photodynamic Therapy in Dermatology
Photodynamic Therapy for Nevus Sebaceus With Topical d-Aminolevulinic Acid
Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses
Dosimetry Model for Photodynamic Therapy With Topically Administered Photosensitizers
